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DESCRIPTION of CASE
A 
35-year-old unemployed man presented to Accident 
and Emergency with a three-day history of progressive 
diplopia and a one-day history of slurred speech. 
There was no history of fever, paraesthesiae, dysphagia, or 
respiratory difﬁ  culty. He admitted drug abuse including 
“muscling” (intramuscular injection of heroin). 
On examination, the patient was well, ambulant, alert, and 
orientated. Vital signs were normal and oxygen saturation was 
97% (room air). There were injection sites in both arms but 
no infected wounds. There were no cardiac murmurs. The 
rest of the general examination was normal.
Visual ﬁ  elds were full and fundi normal. Bilateral partial 
ptosis and complete bilateral ophthalmoplegia were obvious. 
Pupils were dilated and poorly responsive to light, without 
an afferent pupillary defect. Facial muscle power was normal. 
There was dysarthria with absent palatal movements but a 
normal gag reﬂ  ex. No other abnormal neurology was present; 
limb power was normal with preserved deep tendon reﬂ  exes 
and no ataxia. The gait was normal.
Full blood count, and renal and liver function tests 
were within normal limits. C-reactive protein was 3 mg/l 
(normal <10 mg/l). Blood cultures and serum were sent for 
microbiological testing. Chest X ray and electrocardiogram 
were normal. The patient was admitted for observation.
What Is the Likely Diagnosis?
Over a period of three days this patient has developed 
symmetrical paralysis of the ocular and oropharyngeal 
muscles without long-tract signs or sensory deﬁ  cit. Is the 
disease central or peripheral in origin? A central cause is 
difﬁ  cult to envisage since it would involve several cranial 
nerve nuclei yet spare other structures such as corticospinal 
tracts. Peripheral causes may act at the level of motor nerves, 
neuromuscular junction, or muscle. A primary muscular 
cause is unlikely because of the rapid onset of symptoms. 
Motor neuropathies may be acute, e.g., a cranial variant 
of Guillain-Barré syndrome; however features such as 
antecedent illness, paraesthesiae, and loss of reﬂ  exes would 
be expected.
Myasthenia gravis is a common neuromuscular disorder 
that may present relatively acutely. However, pupillary 
dilatation is not observed because antibodies that mediate 
this disease are speciﬁ  c for nicotinic acetylcholine receptors, 
thereby sparing the parasympathetic nervous system. 
Furthermore, total ophthalmoplegia would be very unusual.
The clinical syndrome is typical of wound botulism. 
Botulinum toxin acts pre-synaptically at all peripheral 
cholinergic synapses, blocking neuromuscular junctions as 
well as parasympathetic and sympathetic pathways. Cranial 
nerves are affected before descending weakness of voluntary 
muscles develops. Typical early symptoms are therefore dry 
mouth, blurred vision, diplopia, dysphagia, dysphonia, and 
dysarthria. Pupillary dilatation is common. Limb weakness 
and respiratory compromise may follow rapidly, and the latter 
may occur without the former. Reﬂ  exes are present unless 
ﬂ  accid paralysis becomes severe enough to suppress them. 
The toxin does not cross the blood–brain barrier. Sensory 
disturbance is not a feature of botulism.
A diagnosis of wound botulism is also suggested by the 
history of intramuscular drug injection. The incidence of 
wound botulism following heroin injection into skin or 
muscle has risen dramatically in the United Kingdom since 
2000 [1]. The site of infection may appear benign (as in this 
case) [2], and fever is absent unless wounds are co-infected. 
Gastrointestinal symptoms are not seen in wound botulism. 
Although unlikely, other differential diagnoses to consider 
include diphtheria, tick paralysis, carbon monoxide, or 
organophosphate poisoning. 
What Measures Should Be Instituted Without Delay? 
Wound botulism now carries a case fatality rate of 10%–15% 
compared to rates of 60%–70% in the early 20th century. 
This reduction follows the development of intensive care; 
most patients with botulism require assisted ventilation 
during the course of their illness and the cornerstone of early 
management is prompt recognition and optimal treatment 
of neuromuscular respiratory failure. The patient should be 
placed in a high-intensity facility with regular monitoring 
of vital capacity; a vital capacity less than 30% of predicted 
indicates impending respiratory failure. Patients should not 
eat or drink because of the risk of aspiration; nutritional 
support (enteric or parenteral) should be instituted.
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Progress
The patient was transferred to a neurological ward for 
monitoring and remained nil by mouth. Twelve hours after 
admission he developed dysphagia and weak neck ﬂ  exion 
and extension as well as loss of gag reﬂ  ex. Vital capacity was 
2.0 l (39% of predicted) and arterial blood gas (room air) 
showed pH 7.41, pCO2 4.1 kPa (normal 4.5–6), and pO2 10 
kPa (normal 11–14).
Twenty hours after admission the patient became 
breathless and vital capacity was 0.98 l with arterial blood gas 
(100% oxygen) showing pH 7.29, pCO2 5.8 kPa, and pO2 11.9 
kPa. The patient was electively intubated and ventilated.
What Is the Speciﬁ  c Treatment?
Given the inherent delay in microbiological conﬁ  rmation 
of botulism, botulinum antitoxin should be administered 
as soon as possible after clinical diagnosis. Botulinum 
antitoxin administration is associated with lower mortality 
and shortened clinical course in wound botulism [3]. 
Antitoxin binds free, not intraneuronal, neurotoxin; early 
administration does not reverse the course of intoxication 
but prevents worsening paralysis. Early administration of 
antitoxin is associated with improved outcomes [4,5]. 
A single dose of trivalent (against types A, B, and E) or 
heptavalent (against all types) antitoxin neutralises all free 
neurotoxin, and its half-life of ﬁ  ve to eight days indicates 
that further doses are not helpful if the infection itself is 
treated (see below). Antitoxin is obtained from a reference 
centre (in the UK, the Health Protection Agency, telephone 
0208-200-6868). 10–15 ml serum should be taken prior 
to administration of antitoxin (which rapidly neutralises 
circulating toxin and renders diagnosis impossible).
Antitoxin is an equine derivative and may cause 
anaphylactic reactions; skin testing for sensitivity prior to 
administration is suggested. If there is no reaction, antitoxin 
is administered intravenously, with resuscitation facilities to 
hand.
In wound botulism the toxin is produced in vivo (in food 
botulism toxin is preformed). Treatment of infected wounds 
is required to eradicate the source of toxin. Benzylpenicillin 
and metronidazole are appropriate antibiotics; gentamicin 
may exacerbate neuromuscular blockade. Thorough surgical 
debridement is vital (ideally after antitoxin administration so 
that released toxin is neutralised).
The management of botulism in relatively resource-poor 
settings is difﬁ  cult given the importance of intensive care; 
antitoxin can be obtained from overseas [6], and organism 
eradication applied wherever a case presents. 
Treatment 
Fifteen hours following admission, the patient received a 
single dose of trivalent botulinum antitoxin one hour after a 
negative skin test (0.1 ml intradermal antitoxin). A course of 
intravenous benzylpenicillin was administered.
How Is the Diagnosis Conﬁ  rmed?
Deﬁ  nitive diagnosis of wound botulism can only be 
performed in a reference laboratory and requires culture 
of Clostridium botulinum on anaerobic media from tissue/
pus or identiﬁ  cation of botulinum toxin in serum or other 
samples. The earliest available serum sample should be 
tested. Speciﬁ  c serum toxin detection is conventionally by 
a mouse lethality assay which has a sensitivity of 50% or less 
[1,2]. Immunoassays detecting toxin from a variety of clinical 
sources match the sensitivity of bioassay and provide results 
relatively quickly, but are not yet optimised to detect all 
neurotoxin subtypes. 
Overall, of UK wound botulism cases reported since 
2000, 42% were conﬁ  rmed by toxin detection or culture 
[1]. Hence diagnosis often rests on clinical assessment 
supported by neurophysiological studies (see below); brain 
MRI, cerebrospinal ﬂ  uid examination and measurement of 
anti-acetylcholine receptor antibodies should be undertaken 
to exclude differential diagnoses such as brain-stem infarct, 
Guillain-Barré syndrome, and myasthenia gravis.
Results of Investigations
Botulinum antitoxin bioassay on admission serum was 
negative. Nerve conduction studies showed no evidence of 
demyelinating neuropathy and normal sensory responses. 
Electromyography demonstrated polyphasic motor unit 
potentials, with small amplitude motor responses more than 
doubling in size after exercise. There were decrements on 
repetitive stimulation at low stimulus frequencies with an 
increment at higher rates of stimulation. These ﬁ  ndings 
indicate reversible pre-synaptic neuromuscular junction 
blockade, and are typical of botulism [7]. MRI brain was 
normal, examination of cerebrospinal ﬂ  uid revealed no 
evidence of inﬂ  ammation or elevation in protein level, and 
anti-acetylcholine receptor and HIV antibodies were negative. 
The clinical picture of descending paralysis (in a patient 
practising intramuscular heroin injection) accompanied 
by electrophysiological features of botulism, with normal 
ancillary investigations, provides strong evidence for a 
diagnosis of wound botulism.
Progress
Neurological function began to improve (see Video S1 
performed in intensive care) and extubation was performed 
after 72 hours. Seven days after admission all bulbar signs 
had resolved and oral intake was resumed. The patient 
was discharged three days later and when reviewed in the 
out-patient department at one month had no neurological 
problems. 
DISCUSSION
Wound botulism occurs when spores of C. botulinum 
contaminate a wound, germinate, and produce botulinum 
neurotoxin in vivo. Botulinum toxin cleaves synaptosome-
associated proteins that mediate fusion of vesicles with the 
pre-synaptic membrane in cholinergic synapses, thereby 
inhibiting release of acetylcholine. The cellular receptors for 
both A and B toxin types have now been identiﬁ  ed [8].
Infections by a variety of spore-forming bacteria, particularly 
anaerobic organisms producing neurotoxins (C. botulinum and 
tetani) and histotoxins (C. novyi and others), have undergone 
a dramatic increase in incidence in the UK in the last ﬁ  ve 
years [9]. The reasons for this remain unclear but may involve 
contamination of speciﬁ  c batches of heroin as well as changes 
in injection practices. Since 2000, more than 120 cases of 
wound botulism have been reported in the UK, where this is 
now the most common aetiology of botulism [1].  
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Supporting Information
Video S1. Neurological Examination Demonstrating Physical Signs of 
Botulism
After testing for pupillary reaction to light, the patient is asked to 
look to the left, right, up, and down. Signs include bilateral ptosis, 
loss of pupillary reaction to light, and bilateral ophthalmoplegia 
(with loss of oculocephalic reﬂ  ex). Power and deep tendon reﬂ  exes 
in the limbs are preserved. 
Found at doi:10.1371/journal.pmed.0030453.sv001 (5.6 MB MPG)
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Key Learning Points 
•  In heroin users who inject into skin or muscle, think of spore-
forming bacterial diseases (botulism, tetanus as well as soft 
tissue infection with severe illness).
•  Wound botulism should always be considered in patients with 
ophthalmoplegia.
•  Common early symptoms include diplopia and blurred 
vision although respiratory compromise may occur before 
oculobulbar weakness.
•  Other typical features are: descending symmetrical 
progression; absence of altered mental status or sensory 
abnormality; infected wounds may not be clinically apparent.
Treatment of wound botulism
•  Early detection and management of neuromuscular 
respiratory failure; intense observation for markers of 
impending respiratory failure is vital.
•  Early administration of antitoxin (when clinical diagnosis 
made).
•  Antibiotics (avoid gentamicin).
•  Wound debridement when necessary.
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